Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 17 06 2019
accepted: 30 09 2019
pubmed: 13 11 2019
medline: 5 8 2020
entrez: 13 11 2019
Statut: ppublish

Résumé

Acute naloxone-precipitated morphine withdrawal (MWD) produces a conditioned place aversion (CPA) in rats even after one or two exposures to high-dose (20 mg/kg, sc) morphine followed 24-h later by naloxone (1 mg/kg, sc). However, the somatic withdrawal reactions produced by acute naloxone-precipitated MWD in rats have not been investigated. A recently discovered fatty acid amide, N-oleoylglycine (OlGly), which has been suggested to act as a fatty acid amide hydrolase (FAAH) inhibitor and as a peroxisome proliferator-activated receptor alpha (PPARα) agonist, was previously shown to interfere with a naloxone-precipitated MWD-induced CPA in rats. The aims of these studies were to examine the somatic withdrawal responses produced by acute naloxone-precipitated MWD and determine whether OlGly can also interfere with these responses. Here, we report that following two exposures to morphine (20 mg/kg, sc) each followed by naloxone (1 mg/kg, sc) 24 h later, rats display nausea-like somatic reactions of lying flattened on belly, abdominal contractions and diarrhea, and display increased mouthing movements and loss of body weight. OlGly (5 mg/kg, ip) interfered with naloxone-precipitated MWD-induced abdominal contractions, lying on belly, diarrhea and mouthing movements in male Sprague-Dawley rats, by both a cannabinoid 1 (CB These results suggest that the aversive effects of acute naloxone-precipitated MWD reflect nausea, which is suppressed by OlGly.

Identifiants

pubmed: 31712968
doi: 10.1007/s00213-019-05373-2
pii: 10.1007/s00213-019-05373-2
doi:

Substances chimiques

N-oleoylglycine 0
Narcotic Antagonists 0
Oleic Acids 0
Naloxone 36B82AMQ7N
Morphine 76I7G6D29C
Glycine TE7660XO1C

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

375-384

Subventions

Organisme : Natural Sciences and Engineering Research Council of Canada
ID : 03629
Organisme : Institute of Neurosciences, Mental Health and Addiction
ID : 388239

Références

Neuropsychopharmacology. 2006 Jan;31(1):171-7
pubmed: 15956992
Brain Res. 1978 Mar 24;143(2):263-79
pubmed: 630409
Neuroscience. 1990;37(3):767-73
pubmed: 2247222
Neuropharmacology. 2016 Mar;102:92-102
pubmed: 26541329
Pharmacol Biochem Behav. 1997 Dec;58(4):1003-8
pubmed: 9408206
J Pharmacol Exp Ther. 1977 Apr;201(1):44-54
pubmed: 557543
Neuropharmacology. 2019 Apr;148:320-331
pubmed: 29567093
Physiol Behav. 1992 Nov;52(5):895-9
pubmed: 1336599
J Pharmacol Exp Ther. 1964 Dec;146:385-94
pubmed: 14254334
Neuropharmacology. 2019 Sep 1;155:142-149
pubmed: 31145905
Science. 2007 Oct 26;318(5850):655-8
pubmed: 17962567
Pharmacol Biochem Behav. 2002 May;72(1-2):87-92
pubmed: 11900773
Clin Pharmacol Ther. 1995 Mar;57(3):270-80
pubmed: 7697945
Br J Pharmacol. 2017 Nov;174(21):3837-3847
pubmed: 28805944
J Pharmacol Exp Ther. 2011 Oct;339(1):173-85
pubmed: 21719468
Psychopharmacology (Berl). 2014 Nov;231(22):4291-300
pubmed: 24770676
Life Sci. 1982 Oct 11;31(15):1531-40
pubmed: 6890614
Psychopharmacology (Berl). 2004 Jan;171(2):156-61
pubmed: 13680081
Physiol Behav. 2012 Feb 1;105(3):856-60
pubmed: 22056540
Pharmacol Biochem Behav. 1992 Mar;41(3):559-65
pubmed: 1584835
Psychopharmacology (Berl). 2019 Sep;236(9):2623-2633
pubmed: 30993360
Pharmacol Biochem Behav. 1990 Jun;36(2):393-9
pubmed: 2356213
Psychopharmacology (Berl). 2015 Oct;232(20):3841-8
pubmed: 26297326
Br J Pharmacol. 2010 Sep;161(2):336-49
pubmed: 20735419
Pharmacol Biochem Behav. 1998 Nov;61(3):331-3
pubmed: 9768568
Eur J Pharmacol. 2014 Jan 5;722:122-33
pubmed: 24157975
Psychopharmacology (Berl). 1989;98(4):530-4
pubmed: 2505294
Neuropsychopharmacology. 2016 Jun;41(7):1865-73
pubmed: 26647976
Psychopharmacology (Berl). 2015 Feb;232(3):583-93
pubmed: 25085768
Pharmacopsychiatry. 2009 May;42 Suppl 1:S32-41
pubmed: 19434554
Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
pubmed: 1666911

Auteurs

Erin M Rock (EM)

Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Samantha M Ayoub (SM)

Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Cheryl L Limebeer (CL)

Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Alexia Gene (A)

Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Kiri L Wills (KL)

Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Marieka V DeVuono (MV)

Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada.

Reem Smoum (R)

Institute for Drug Research, Medical Faculty, Hebrew University, Jerusalem, Israel.

Vincenzo Di Marzo (V)

Institute of Biomolecular Chemistry, Endocannabinoid Research Group, Consiglio Nazionale delle Richerche, Pozzuli, Naples, Italy.
Canada Excellence Research Chair on the Microbiome/Endocannabinoid Axis in Metabolomic Health, University of Laval, Quebec City, Canada.

Aron H Lichtman (AH)

Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.

Raphael Mechoulam (R)

Institute for Drug Research, Medical Faculty, Hebrew University, Jerusalem, Israel.

Linda A Parker (LA)

Department of Psychology and Collaborative Neuroscience Program, University of Guelph, Guelph, ON, N1G 2W1, Canada. parkerl@uoguelph.ca.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH